Tvardi Therapeutics

Tvardi Therapeutics Announces Publication Demonstrating TTI-101 as a Therapeutic Option for Treatment-Resistant Breast Cancers

Tvardi Therapeutics (“Tvardi”), a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, announced the publication of preclinical studies establishing that its lead compound, TTI-101, is effective against treatment-resistant breast cancers. The paper, published in Clinical Cancer Research, elucidated the STAT3 pathway as the mechanism of resistance and demonstrated that TTI-101 overcame this resistance …

Tvardi Therapeutics Announces Publication Demonstrating TTI-101 as a Therapeutic Option for Treatment-Resistant Breast Cancers Read More »